therapeutics glp 1 activate reviews Frontiers GLP-1 Drugs and the Physiology

For NYC patients approaching Medicare or already enrolled in Part D, this may become an important bridge between todays uneven obesity-drug coverage and broader future access

Improvements in visceral adiposity exceeded those observed in the comparator group receiving a sodium-glucose cotransporter 2 (SGLT2) inhibitor

The rationale behind the combination is scientifically grounded

Lilly CEO David Ricks framed the approval in terms of access: " Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment, " Ricks said in the company's April 1 press release

The Takeaway The new report doesnt revolutionize diabetes careit refines it

Diabetes Res Clin Pract 119:112